Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Effects of A1AT on PCSK9 expression and function

Award Number: SC1GM131974
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/09/2019
PERIOD OF PERFORMANCE END DATE: 03/31/2024

Group Awards By:

View Award Description

Effects of A1AT on PCSK9 expression and function - PROJECT SUMMARY Heart disease is the principal cause of death and disability for both men and women in the US accounting for 40% of all annual deaths. A high cholesterol level, especially of low density lipoprotein (LDL), is a well-known risk factor for this disease. The key atherogenic property of LDL particles involves the formation of atherosclerotic plaques. Since the hepatic LDL receptor is the major determinant of plasma LDL-cholesterol levels, a greater understanding of the regulatory mechanisms that control the expression of the LDL receptor is essential. Proprotein convertase subtilisin/kexin-9 (PCSK9) is a well-known indirect regulator of plasma LDL levels by controlling the number of LDL receptor molecules expressed at the plasma membrane. Preliminary studies in our laboratory suggest that alpha-1-antitrypsin (A1AT) directly interacts with PCSK9 in the medium of cells and prevents the formation of PCSK9/LDL receptor complexes in vitro. A1AT also promotes the removal of PCSK9 from the medium of the cells, but the mechanism for this removal is currently unknown. The long-term objective of this research project is to characterize the molecular mechanisms involved in the A1AT-dependent regulation of PCSK9 expression and function. The major impact of this project will be the identification of an endogenous inhibitor of PCSK9 could lead to the development of diagnostic tests to identify patients and provide them with the best and safest treatment options. Also, this inhibitor could become an alternative treatment for patients that develop intolerance to currently available anticholesterolemic drugs. Based on this, we hypothesized that the levels of LDL receptor protein that is available to bind and remove LDL from the circulation are conditioned to the ratio between A1AT and PCSK9. In this research proposal, we will test this hypothesis through the following specific aims: Aim I: To find common regulators of A1AT and PCSK9 expression; Aim II: To detect critical protein regions in A1AT that influences PCSK9 expression/function; Aim III: To identify the pathway(s) involved in the internalization of PCSK9/A1AT complexes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	NORTH CAROLINA CENTRAL UNIVERSITY	1801 FAYETTEVILLE ST	DURHAM	NC	27707	DURHAM	USA	Biomedical Research and Research Training	000	4	8/28/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $370,000 )
2022	2022	NORTH CAROLINA CENTRAL UNIVERSITY	1801 FAYETTEVILLE ST	DURHAM	NC	27707	DURHAM	USA	Biomedical Research and Research Training	000	4	7/12/2022	NON-COMPETING CONTINUATION	$370,000
														Subtotal = $370,000

Issue Date FY: 2021 ( Subtotal = $370,000 )
2021	2021	NORTH CAROLINA CENTRAL UNIVERSITY	1801 FAYETTEVILLE ST	DURHAM	NC	27707	DURHAM	USA	Biomedical Research and Research Training	000	3	7/29/2021	NON-COMPETING CONTINUATION	$370,000
														Subtotal = $370,000

Issue Date FY: 2020 ( Subtotal = $370,000 )
2020	2020	NORTH CAROLINA CENTRAL UNIVERSITY	1801 FAYETTEVILLE ST	DURHAM	NC	27707	DURHAM	USA	Biomedical Research and Research Training	000	2	7/28/2020	NON-COMPETING CONTINUATION	$370,000
														Subtotal = $370,000

Issue Date FY: 2019 ( Subtotal = $370,000 )
2019	2019	NORTH CAROLINA CENTRAL UNIVERSITY	1801 FAYETTEVILLE ST	DURHAM	NC	27707	DURHAM	USA	Biomedical Research and Research Training	000	1	8/9/2019	NEW	$370,000
														Subtotal = $370,000

Grand Total All Awards = $1,480,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Effects of A1AT on PCSK9 expression and function

Award Number: SC1GM131974

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/09/2019

PERIOD OF PERFORMANCE END DATE: 03/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer